X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50) 50
female (48) 48
oncology (47) 47
index medicus (46) 46
breast cancer (37) 37
middle aged (33) 33
aged (31) 31
breast neoplasms - drug therapy (30) 30
adult (28) 28
breast neoplasms - pathology (26) 26
chemotherapy (24) 24
prognosis (19) 19
cancer (18) 18
treatment outcome (16) 16
aged, 80 and over (15) 15
care and treatment (14) 14
androgen receptor (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
bevacizumab (12) 12
breast neoplasms - metabolism (12) 12
health aspects (12) 12
metastasis (12) 12
neoplasm staging (12) 12
women (12) 12
tumors (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
medicine & public health (10) 10
subtypes (10) 10
antibodies, monoclonal, humanized (9) 9
hematology, oncology and palliative medicine (9) 9
neoplasm metastasis (9) 9
antibodies, monoclonal - administration & dosage (8) 8
antineoplastic agents - administration & dosage (8) 8
antineoplastic agents - therapeutic use (8) 8
breast neoplasms - genetics (8) 8
clinical trials (8) 8
estrogen (8) 8
expression (8) 8
paclitaxel (8) 8
receptor, erbb-2 - metabolism (8) 8
surgery (8) 8
androgens (7) 7
animals (7) 7
cancer therapies (7) 7
dose-response relationship, drug (7) 7
drug administration schedule (7) 7
drug therapy (7) 7
paclitaxel - administration & dosage (7) 7
prostate-cancer (7) 7
receptors, androgen - metabolism (7) 7
triple-negative breast cancer (7) 7
abiraterone acetate (6) 6
antibodies, monoclonal - adverse effects (6) 6
bicalutamide (6) 6
carcinoma (6) 6
endocrine therapy (6) 6
follow-up studies (6) 6
male (6) 6
prostate cancer (6) 6
receptors, estrogen - metabolism (6) 6
receptors, progesterone - metabolism (6) 6
recurrence (6) 6
risk factors (6) 6
survival (6) 6
therapy (6) 6
triple negative breast neoplasms - drug therapy (6) 6
abridged index medicus (5) 5
adjuvant chemotherapy (5) 5
analysis (5) 5
antineoplastic agents - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
biopsy (5) 5
breast neoplasms - mortality (5) 5
capecitabine (5) 5
chemotherapy, adjuvant (5) 5
comorbidity (5) 5
development and progression (5) 5
disease-free survival (5) 5
efficacy (5) 5
enzalutamide (5) 5
epidemiology (5) 5
feasibility studies (5) 5
fluorouracil - administration & dosage (5) 5
identification (5) 5
immunohistochemistry (5) 5
mastectomy (5) 5
original reports (5) 5
patients (5) 5
randomized-trial (5) 5
retrospective studies (5) 5
risk (5) 5
young adult (5) 5
antineoplastic agents - pharmacology (4) 4
clinical trials as topic (4) 4
combination (4) 4
cyclophosphamide - administration & dosage (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
diagnosis (4) 4
dosage and administration (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Breast Cancer: Targets and Therapy, ISSN 1179-1314, 2014, Volume 6, pp. 123 - 133
Journal Article
Cancer, ISSN 0008-543X, 05/2017, Volume 123, Issue 10, pp. 1686 - 1688
Journal Article
Breast, The, ISSN 0960-9776, 2015, Volume 24, pp. S27 - S28
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4046 - 4054
Purpose: Several lines of evidence support targeting the androgen signaling pathway in breast cancer. Enzalutamide is a potent inhibitor of androgen receptor... 
ANDROGEN RECEPTOR | MASS-SPECTROMETRY METHOD | PLASMA | EXEMESTANE | ANTIANDROGEN | ONCOLOGY | FULVESTRANT | PROSTATE-CANCER | AROMATASE INHIBITORS | ER-ALPHA | ANASTROZOLE | Phenylthiohydantoin - adverse effects | Triazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Progesterone - genetics | Drug-Related Side Effects and Adverse Reactions - pathology | Antineoplastic Agents, Hormonal - pharmacokinetics | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Cytochrome P-450 CYP3A - genetics | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | Antineoplastic Agents, Hormonal - administration & dosage | Breast Neoplasms - drug therapy | Phenylthiohydantoin - analogs & derivatives | Phenylthiohydantoin - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Aged | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - classification | Phenylthiohydantoin - pharmacokinetics | Cytochrome | Anastrozole | Estrogens | Cytochrome P450 | Estrogen | Estrogen receptors | Breast cancer | Pharmacology | Exposure | Patients | Fulvestrant | Signal transduction | Signaling | Androgens | Experimental design | Safety engineering | Progesterone | Prostate cancer | Prostate | Cancer
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2018, Volume 171, Issue 1, pp. 111 - 120
Journal Article
Clinical cancer research, ISSN 1557-3265, 2013, Volume 19, Issue 19, pp. 5505 - 5512
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 17, pp. 1902 - 1909
Journal Article
Endocrine-related cancer, ISSN 1479-6821, 2015, Volume 22, Issue 3, pp. R87 - R106
Journal Article